In the PAH model, NF-κB signaling is activated, and sevoflurane can modulate NF-κB signaling by inhibiting p-IκB, p-p65, and p65 levels, reducing pulmonary fibrosis, and preventing PAH [40]. The gene discussed is NFKB1; the disease is pulmonary arterial hypertension.